Biotech and pharmaceutical organizations face increasing pressure to strengthen cybersecurity as regulations tighten and cyberattacks become more sophisticated. Protecting sensitive assets such as drug formulas, clinical trial data, and manufacturing systems requires more than traditional perimeter defenses. Network segmentation, particularly microsegmentation, has become essential, as most breaches involve lateral movement within systems. Regulatory frameworks like FDA 21 CFR Part 11 and IEC 62443 now emphasize segmentation as a critical control. By isolating systems and limiting access, companies can better safeguard operations, reduce risk, and ensure the integrity and continuity of critical healthcare processes.

Join for free to read